Intraepithelial corneal deposits associated with Mirvetuximab soravtansine use for platinum-resistant ovarian cancer.

Purpose: Present a case of Mirvetuximab soravtansine (MIRV)-induced intraepithelial corneal deposits, review a proposed mechanism to explain the blurred vision our patient experienced, and explain clinical exams that may be used to support the diagnosis.

Observations: A 63-year-old female with metastatic ovarian cancer diagnosed with intraepithelial corneal deposits two weeks after her first MIRV infusion. Treatment with topical prednisolone acetate 1 % ophthalmic suspension and lubricating eye drops without interruption of her MIRV infusions resulted in complete resolution of blurry vision and corneal deposits.